CoronaryAtlas logo
CoronaryAtlas
Plasminogen Activator, Urokinase
Pathway / Fibrous-cap degradation & rupture

Plasminogen Activator, Urokinase

PLAUgene

PLAU encodes urokinase, a serine protease that degrades fibrin and extracellular matrix, contributing to fibrous-cap rupture and thrombus formation.

Pathway placement
Cascade stepFibrous-cap degradation & rupture
Confidencehigh
RationaleUrokinase drives fibrin degradation and ECM remodeling during cap rupture.
Also acts inCoagulation / thrombus
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000122861

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
52
C — confounder / Type-II
52
A — assay feasibility
52
E — evidence strength
22
T1DI (composite)
6
Specificity differential (R−C)+0.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable

Human genetic evidence

0.491
Open Targets association (myocardial_infarction)

Literature evidence(2)